Outsourced Manufacturing: A Swiss Specialty
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard…
Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company. As one of the first companies…
Worldwide, severe side effects from classic medicine are becoming a health risk in themselves, often misdiagnosed as symptoms of other problems, resulting in further prescriptions, further side effects and unanticipated drug interactions;…
In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants,…
Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful…
Basel-headquartered pharma giant Novartis announced its financial results for 2018 this week, showcasing full year net sales growth of five percent driven by the strong performance of the company’s pharmaceutical…
The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined…
In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models,…
The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director general…
As the spotlight turns towards optimising supply and delivery chains in pharma logistics, Swiss Post has distinguished itself as one of the early movers in trialling autonomous drone logistics for…
Alexander Bauer, chairman and co-founder of 4PL Central Station, introduces his company’s unique logistics service offering, and the role of fourth party logistics in the future of the pharmaceutical industry.…
See our Cookie Privacy Policy Here
